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Objectives. This study was designed to examine whether or not
intramural delivery of ST638 (a specific tyrosine kinase inhibitor)
with biodegradable stent can suppress the restenotic changes of
the coronary artery in vivo.
Background. Clinical and animal studies demonstrated that
restenosis after coronary intervention results from a combined
effect of neointimal formation and geometric remodeling (de-
crease in total cross-sectional area). Thus, the most effective
strategy to prevent the restenosis appears to inhibit both the
neointimal formation and geometric remodeling by antiprolifera-
tive agent and stent, respectively. We have previously shown that
ST638 markedly suppresses the restenotic changes of the porcine
coronary artery when applied from the adventitial site.
Methods. A poly-L-lactic acid biodegradable stent was coated
with either ST638 (0.8 mg) or equimolar of its inactive metabolite,
ST494. A pair of these stents were implanted alternatively in the
left anterior descending or circumflex coronary artery in pigs (n 5
6). Three weeks after the procedure, coronary stenosis was
assessed by angiography followed by histological examination.
Results. Coronary stenosis was significantly less at the ST638
stent site than at the ST494 stent site (47 6 5% vs. 25 6 4%, p <
0.01). Histological examination also showed that the extent of
neointimal formation and that of geometric remodeling were
significantly less at the ST638 stent site than at the ST494 stent
site (p < 0.05).
Conclusions. These results indicate that intramural delivery of
a specific tyrosine kinase inhibitor with biodegradable stent
overcomes the proliferative stimuli caused by balloon injury, the
stent itself, and the drug coating on the stent, resulting in the
suppression of the restenotic changes of the coronary artery in
vivo. This strategy might also be useful in the clinical setting in
humans.
(J Am Coll Cardiol 1998;32:780–6)
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Percutaneous transluminal coronary angioplasty (PTCA) is a
widely accepted treatment for coronary artery disease. How-
ever, the usefulness of PTCA is limited by restenosis, which
occurs in 30–40% of patients within 3–6 months after the
procedure (1,2). The restenosis after PTCA is currently under-
stood as a combined process of neointimal formation and
geometric remodeling in response to balloon injury (3). There-
fore, the strategy to suppress both the neointimal formation by
antiproliferative drugs and the geometric remodeling by stent
(4,5) appears to be a reasonable approach to overcome the
restenosis after PTCA.
After balloon angioplasty, a series of interactions between
blood elements and the vessel wall occurs, which then pro-
motes the migration and proliferation of smooth muscle cells
within the intima (6,7). These processes are known to be
induced by growth factors, such as platelet-derived growth
factor (PDGF), fibroblast growth factor-2, and insulin-like
growth factor-1, and by deposition of extracellular matrix
components (8–12). Receptors for these growth factors have
tyrosine kinase activities and phosphorylate their own tyrosine
residues upon ligand binding (13). Therefore, tyrosine kinases
are important transducers of a variety of extracellular signals
that regulate proliferation, differentiation, and specific func-
tions of differentiated cells (14). Indeed, we have previously
shown that neointimal formation of the coronary artery in-
duced by chronic treatment with interleukin-1 beta (IL-1b)
(15) or PDGF (16), or by balloon injury (17), is markedly
suppressed by ST638, a specific tyrosine kinase inhibitor,
applied from the adventitial site in pigs. Since the coronary
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lesions in those animal models are similar to those in human
restenotic lesions, ST638 might also be effective to prevent the
neointimal formation after PTCA in humans.
Synthetic polymers are more suitable than metals as a
material of stent in terms of compliance and tissue responses,
as well as a vehicle for intramural drug delivery (18–24).
Poly-L-lactic acid (PLLA) is a biodegradable polymer that
could potentially be used in many clinical situations (25–27).
PLLA is suitable as a material for stent because the collapse
pressure of the stents made from the polymer surpasses
300 mm Hg and its disintegrated half-life is 60–90 d, which is
enough to prevent the geometric remodeling of the coronary
artery after PTCA (28–30).
Methods
Materials. PLLA stents (Igaki-Tamai stent; Igaki Medical
Planning) (31) were made of 120-mm PLLA thread (molecular
mass ;185 kD), folded over a tubular device. The stents were
loaded with 0.8 mg ST638 (a-cyano-3-ethoxy-4-hydroxy-5-
phenyl-methylcinnamamide, Kaneka Co.) or equal molar
ST494, as an inactive control, which is a nonactive conductor of
ST638 (32). To load ST638 or ST494 steadily and smoothly,
poly-«-caprolactone, one of the biodegradable polymer, was
coated on PLLA stents with these drugs (33). This coating
process was performed under sterile conditions. Drug-loaded
PLLA stents were then mounted on standard angioplasty
balloon catheters (manufacture-specified balloon diameter,
3.0 mm). The whole implant systems were produced in a clean
laboratory environment.
Animal preparation. Fourteen male domestic pigs (Nihon
Crea Inc.) 2–3 months old and weighing 25–30 kg, were
pretreated with aspirin (325 mg PO) daily for 5 days before the
procedure, and continued throughout the experimental period.
On the day of the stent implantation, the animals were sedated
with ketamine hydrochloride (1.25 mg/kg IM) and were then
anesthetized with sodium pentobarbital (20 mg/kg IV) (15,16).
They were then intubated and ventilated with room air, and
oxygen was supplemented via a positive-pressure respirator
(Shinano Inc.). Arterial pH, pO2, and pCO2 were kept within
normal ranges. Under aseptic conditions, the left carotid artery
was surgically exposed, and a 10-F sheath was inserted. After
systemic heparinization (10,000 U IV), angiograms of the left
coronary arteries were performed with a femoral Judkins
guiding catheter (10F, Medtronic Inc.). A PLLA stent loaded
with either ST638 (ST638 stent) or ST494 (control stent) was
implanted alternatively to the proximal segment of either the
left anterior or the left circumflex coronary arteries. The
coronary artery for the stenting was randomized. Arteriotomy
was then repaired, the skin was closed, and the animals were
allowed to recover from anesthesia.
Three weeks after the procedure, six animals again under-
went coronary arteriography. They were then euthanized with
a lethal dose of sodium pentobarbital and exsanguinated, and
the left coronary arteries were perfusion-fixed for histological
analysis. Another eight animals were sacrificed 0, 3, 7, and 21 d
(two animals in each period) after the stent implantation to
determine the ST638 release in vivo.
The experiment was reviewed by the Committee of the
Ethics on Animal Experiment at the Kyushu University School
of Medicine and was carried out under the control of the
Guidelines for Animal Experiment at the Kyushu University
School of Medicine and The Law (No. 105) and Notification
(No. 6) of the Japanese Government.
ST638 Release from PLLA stent in vitro and its pharma-
cokinetics in vivo. To investigate the release of ST638 from
the PLLA stent in vitro, an ST638 stent was immersed in 1 mL
of fetal calf serum at room temperature for 1–21 d. Fetal calf
serum was replaced daily, and the amount of ST638 released
into the serum was quantified by high-performance liquid
chromatography (HPLC) (15).
To determine the pharmacokinetics of ST638 in the porcine
coronary artery in vivo, the coronary artery with the ST638
stent was taken out immediately after and 3, 7, and 14 d after
the implantation of the ST638 stent. The amount of ST638 was
quantified by HPLC and expressed as its concentration of per
1 g wet weight of the vessel.
Stent implantation in vivo. The ST638 or control stent was
mounted under sterile conditions on the angioplasty catheter
(diameter 3.0 mm). On the basis of the angiograms, the
proximal segment with a diameter of 2.5–3.0 mm was selected
in both the left anterior descending and the left circumflex
coronary artery, so that the balloon-to-artery diameter ratio
was approximately 1.2. An angioplasty catheter with the ST638
or control stent was then advanced to one of the two coronary
segments for implantation over a standard PTCA guide wire.
The balloon catheter was inflated at 8 atmospheres for 30 s two
times at an interval of 2 min, and was then slowly withdrawn,
leaving the stent in place. The coronary segment for stent
implantation was randomized. After the angiography of the
stented coronary arteries to assure the vessel patency, all
equipments were removed, and the carotid artery was ligated.
Coronary angiography and hemodynamic measurements.
Selective coronary angiography was performed before, imme-
diately after, and 3 wk after the stent implantation. A pre-
shaped Judkins catheter was inserted into the right or left
carotid artery, and coronary angiography in a left oblique view
was performed. Electrocardiograms in leads I, II, III, V1, and
V6 were recorded. Arterial pressure was measured with a
pressure transducer (Gould Inc.) connected to a Judkins
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catheter. The arterial pressure, heart rate, and electrocardio-
grams were continuously monitored and recorded on a pen
recorder (NEC San-Ei Polygraph System) throughout the
procedure (15,16).
Selective coronary angiography was performed in a left
anterior oblique projection that allowed a clear visualization of
the stent implantation site, using the Toshiba cineangiography
system (KKO-1250/CAS-CA, Toshiba Medical Inc.) (15–17).
The angiograms were recorded on 35-mm cinefilm (Varicath I,
VARIX) at 48 frames per second. The angle of the projection,
the posture of the animal, and the distance from x-ray focus to
the object and that from the object to the image intensifier
were carefully kept constant during each experiment (15–17).
Cineangiograms were projected on a screen using a cineprojec-
tor (ELK-35CB, Nishimoto Sangyo Inc.), and an end-diastolic
frame was selected. The coronary luminal diameters were
measured with a caliper (15–17). Using this technique, excel-
lent correlations between repeated measurements (r 5 0.99)
and between repeated different observers (r 5 0.98) were
confirmed in the range of the coronary diameter from 0.98 to
5.58 mm (15–17). The coronary diameter, where either ST638
or control stent was applied, was comparable with the site just
proximal to the stent implantation segment.
Histopathological study. The animals were then sacrificed
with a lethal dose of sodium pentobarbital, exsanguinated, and
then the heart was excised. The left coronary artery was
perfused with 6% formalin at 120 mm Hg and fixed with
formalin for 1 wk. For the light microscopic examination, tissue
samples were embedded in paraffin, sectioned into 5-mm-thick
slices, mounted on glass slides, and stained with hematoxylin-
eosin and van Gieson’s methods.
The intimal and medial areas were measured in photomi-
crographs by a computer-assisted picture analysis system (Gen-
locker System; Sony) (15–17). The intimal area and medial
area were calculated by measuring the internal border of the
vessel (lumen area), the area encircled by the internal elastic
lamina (IEL area), and the area encircled by the external
elastic lamina (EEL area). The degree of the neointimal
formation was expressed by the intimal area/medial area ratio
(I/M ratio) (15–17). The degree of the vascular remodeling was
expressed by the change in the three vessel areas (lumen area,
IEL area, and EEL area), which were calculated by the
formula: (ATx 2 ACONT)/ACONT 3 100 (%), where ATx and
ACONT are the vessel areas of the coronary segments at the
treated (stent implanted) site and at the adjacent control site,
respectively. The geometric remodeling was defined as the
reduction of the IEL and EEL areas (15,16).
Statistical analysis. The results are expressed as mean 6
SEM. Throughout the text and in the figures, n represents the
number of animals examined. Multiple comparisons were
made by analysis of variance for repeated examinations fol-
lowed by a Scheffe’s post-hoc test. Paired data were analyzed
by Student’s t-test. A p value of ,0.05 was considered to be
statistically significant.
Results
ST638 release from PLLA stent in vitro and its pharmaco-
kinetics in vivo. ST638 was released linearly into fetal calf
serum from the PLLA stent for the initial 2 wk, followed by
gradual release until day 21 in vitro (Fig. 1A). The concentra-
tion of ST638 in the porcine coronary artery implanted with
ST638 was exponentially decreased until day 21 in vivo (Fig.
1B). The estimated local concentration of ST638 in the arterial
wall at 0, 3, 7, and 21 d after the implantation was 2.0, 0.98,
0.46, 0.023 mmol/L, respectively, while regarding 1 g of wet
weight of the vessel as 1 mL of fluid. The estimated local
concentration of ST638 at day 0 was thus 100 times higher than
that at day 21, which was equivalent to the minimal effective
concentration of the inhibitor (0.025 mmol/L), which inhibits
intracellular tyrosine kinases, such as tyrosine kinase of epi-
dermal growth factor (EGF) receptor (32).
Coronary diameters and hemodynamic variables. Before
the stent implantation, there was no significant difference in
the coronary diameters between the coronary segments im-
planted with the ST638 or control stent (Table 1). However,
3 wk after the stent implantation, the diameter of the coronary
segment implanted with the ST638 or control stent was signif-
icantly decreased, whereas the diameter was significantly
greater at the ST638 stent site than at the ST494 stent site
(Table 1). In contrast, the diameter of the untreated segment
remained unchanged before and 3 wk after the stent implan-
tation (Table 1). There was no significant difference in blood
Figure 1. A, Cumulative ST638 release from PLLA stent over a 3-wk
period as a percentage of the initial loaded ST638 in vitro. Each data
point represents the mean of two measurements. B, Local concentra-
tion of ST638 in the porcine coronary arteries implanted with the
ST638 stent at 0, 3, 7, and 21 d after stent implantation in vivo.
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pressure or heart rate before or 3 wk after the stent implan-
tation (Table 1).
Effects of ST638 on the development of angiographic coro-
nary stenosis. A moderate stenotic lesion was noted at the
stent site, however, the degree of the angiographic coronary
stenosis was significantly less at the ST638 stent site than at the
control stent site (Figs. 2 and 3).
Histological study. The balloon-to-artery ratio was compa-
rable between the sites implanted with either the ST638 or
control stent (1.2 6 0.1 vs. 1.2 6 0.1). Three weeks after the
stent implantation, neointimal formation was noted at the
stent-implanted site, where the neointima was occupied by
migrated smooth muscle cells, whereas no severe inflammatory
response was observed around the polymer thread (Fig. 4).
The extent of the neointimal formation was significantly sup-
pressed at the ST638 stent site compared with the control stent
site (Figs. 4 and 5).
When the cross-sectional areas of the coronary artery were
analyzed, the EEL and IEL areas were significantly increased
at the stent-implanted sites, and the extent of the vessel
enlargement was significantly greater at the ST638 stent site
compared with that at the control stent site (Fig. 6).
Discussion
The novel findings of the present study in porcine coronary
arteries were that: (1) the PLLA stent was useful in delivering
a drug into the coronary arterial wall, although it caused
neointimal formation and angiographic stenosis; and (2) intra-
mural delivery of a specific tyrosine kinase inhibitor, ST638,
significantly suppressed the stent-induced restenotic changes
of the porcine coronary artery. To the best of our knowledge,
this is the first report of a successful intramural delivery of an
antiproliferative agent into the coronary artery with a biode-
gradable stent that resulted in the suppression of the restenotic
changes of the coronary artery in vivo.
Biodegradable PLLA stent as a tool for local drug delivery.
PLLA is a completely biodegradable material that can be
degraded by hydrolysis, either nonenzymatically or enzymati-
cally, and can be eliminated through carbon dioxide in the
respiration (25). Schakenraad et al. (29) demonstrated that
PLLA fibers cause only a mild foreign body reaction, and thus
Figure 2. Coronary angiograms in a pig. A, Before stent implantation;
B, immediately after stent implantation; and C, 3 wk after stent
implantation. The white arrow indicates the site implanted with ST638
stent, and the black arrow shows the site implanted with control stent.
Table 1. Coronary Diameters and Hemodynamic Variables Before and After Coronary Stenting
in Pigs
n
Coronary diameter (mm)
mBP
(mm Hg)
HR
(bpm)No Tx
Control
Stent ST638 Stent
Before stenting 6 2.52 6 0.12 2.66 6 0.08 2.64 6 0.19 115.8 6 3.5 164.2 6 9.0
3 weeks after
stenting
6 2.53 6 0.10 1.45 6 0.12* 1.98 6 0.13*† 110.8 6 3.7 153.2 6 7.9
Data are expressed as mean 6 SEM. No Tx 5 untreated coronary segment; mBP 5 mean blood pressure; HR 5
heart rate. *p , 0.01 vs. before stenting, †p , 0.05 vs. control stent.
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have a very low inflammatory potential during the wound
healing process. Several studies have investigated the potential
usefulness of PLLA as a material for a bioabsorbable stent.
Agrawal et al. (30) showed that PLLA provides adequate
strength to the stent as the collapse pressure of the PLLA
stents surpasses 300 mm Hg. Chapman et al. (18) demon-
strated that the PLLA stent is endothelialized 2 wk after the
implantation and remains patent without inducing any signif-
icant inflammatory or thrombotic responses for the subsequent
12 wk after the implantation in dogs in vivo. Indeed, in the
present study, the EEL and IEL areas were greater at the stent
sites (with either ST638 or ST494) than those at the adjacent
control sites, indicating that the PLLA stent prevented the
geometric remodeling.
However, Giessen et al. (34) recently reported that both
biodegradable and nonbiodegradable polymers induce marked
inflammatory reaction with subsequent massive neointimal
formation in porcine coronary arteries. In the present study,
we also noted the neointimal formation caused by PLLA
stents, however, the degree of the neointimal formation was
less than that reported by Giessen et al. (34) and less inflam-
matory response was noted. Lincoff et al. (35) recently dem-
onstrated that low molecular mass (;80 kD) PLLA causes an
intense inflammatory neointimal response, whereas high mo-
lecular mass (;321 kD) PLLA is well tolerated within the
coronary artery with no evidence of associated cellular inflam-
mation, which is consistent with our present finding.
We consider that the neointimal formation in the present
study was not due to the effect of coating materials because the
neointimal formation was also observed with a plain stent
without any drug or with a stent with poly-«-caprolactone alone
(data not shown). This tissue reaction may be attributable to a
combination of parent polymer compound, biodegradable
products, and damage due to the asymmetric geometry of the
stent. Moreover, these reactions might be specific to the
porcine artery because none of the other animal studies have
shown such a tissue reaction (18,25). Therefore, it is unclear at
present whether or not similar tissue reaction is induced by a
PLLA stent in the human coronary artery.
ST638 as an antiproliferative agent in vivo. ST638 potently
and selectively inhibits tyrosine-specific kinase activity of the
epidermal growth factor (EGF) receptor with an IC50 value of
0.37 mM, and has no inhibitory effect on the enzymes of serine-
and/or threonine-specific protein kinase, such as cAMP-
dependent protein kinase, Ca21/phospholipid-dependent pro-
tein kinase C, casein kinase I, or casein kinase II (32). Its
inhibitory effect is mediated by competing with the substrate
protein for the tyrosine kinase binding site (32). We previously
demonstrated that ST638 applied from the adventitial site
markedly suppresses the neointimal formation and geometric
Figure 3. Angiographic coronary stenosis 3 wk after implantation with
the ST638 or control stent.
A
C
B
Figure 4. Photomicrograph of the stented coronary segments 3 wk
after stent implantation. A, Neointima and media around the PLLA
stent thread. I, Neointima; M, media; A, adventitia; S, stent thread
(3400). B, A coronary segment implanted with the control stent
(340). C, A coronary segment implanted with the ST638 stent (340).
Calibration: 0.1 mm for A, and 1.0 mm for B and C.
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remodeling induced by IL-1b (15), PDGF (16), and balloon
injury (17) in vivo. These inhibitory effects of ST638 were
indeed the result of the inhibition of tyrosine kinases because
ST638 markedly suppresses the tyrosine phosphorylations in-
duced by IL-1b (15), PDGF (16), and balloon injury (17). It is
highly possible in the present study that the antiproliferative
effects of ST638 overcame the proliferative stimuli caused by
balloon injury, the stent itself, and the drug coating on the
stent, resulting in the inhibition of the development of neoin-
timal formation after the stent implantation in vivo. Lincoff et
al. (35) recently succeeded in delivering dexamethasone into
the porcine coronary artery with PLLA-coated tantalum wire
stent. Although the local concentrations of dexamethasone
were high enough, the steroid did not reduce the neointimal
formation (35). Thus, a specific tyrosine kinase inhibitor (such
as ST638) may be more useful than steroids to inhibit the
neointimal formation in vivo, at least in the porcine model of
stent arterial injury.
The present study demonstrated that ST638 could also
prevent the geometric remodeling of the coronary artery after
stenting in vivo. This result is consistent with our previous
findings that ST638 applied from the adventitia inhibited the
geometric remodeling induced by IL-1b (15), PDGF (16), or
balloon injury (17).
Study limitations. Although the present study demon-
strates the possible usefulness of a PLLA stent with a specific
tyrosine kinase inhibitor to suppress the restenotic changes,
several limitations could be raised. First, although local con-
centrations of ST638 were maintained above the effective
concentration over 21 d after the stenting, neointimal forma-
tion was not completely prevented. It is conceivable that local
concentrations of ST638 in the coronary artery were higher
near the stent compared with the distant portion. Thus, it is
necessary to develop a material that can deliver a larger
amount of an antiproliferative drug and can release it for a
longer period. Second, although the present study demon-
strated the short-term biocompatability of our PLLA stent, the
long-term biocompatability was not tested. Thus, such an
examination appears to be required before the clinical use of
our stent could be considered.
Summary. In summary, we were able to demonstrate that
the biodegradable PLLA stent is useful in preventing geomet-
ric remodeling, although it causes neointimal formation, and
that the intramural delivery of the specific tyrosine kinase
inhibitor, ST638, significantly suppresses the restenotic
changes after the PLLA stent implantation in the porcine
coronary artery in vivo. Further studies are needed, however,
to confirm the usefulness of the present strategy to use a
specific tyrosine kinase inhibitor and a biodegradable stent to
reduce the restenosis after successful PTCA in humans.
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